RESUMEN
In this work, various dispersion compensation methods are designed and evaluated to search for a cost-effective technique with remarkable dispersion compensation and a good pulse shape. The techniques consist of different chirp functions applied to a tanh fiber Bragg grating (FBG), a dispersion compensation fiber (DCF), and a DCF merged with an optimized linearly chirped tanh FBG (joint technique). The techniques are evaluated using a standard 10 Gb/s optical link over a 100 km long haul. The linear chirp function is the most appropriate choice of chirping function, with a pulse width reduction percentage (PWRP) of 75.15%, lower price, and poor pulse shape. The DCF yields an enhanced PWRP of 93.34% with a better pulse quality; however, it is the most costly of the evaluated techniques. Finally, the joint technique achieved the optimum PWRP (96.36%) among all the evaluated techniques and exhibited a remarkable pulse shape; it is less costly than the DCF, but more expensive than the chirped tanh FBG.
RESUMEN
BACKGROUND: The novel SARS-CoV-2 vaccines partially exploit intrinsic DNA or RNA adjuvanticity, with dysregulation in the metabolism of both these nucleic acids independently linked to triggering experimental autoimmune diseases, including lupus and myositis. METHODS: Herein, we present 15 new onset autoimmune myositis temporally associated with SARS-CoV-2 RNA or DNA-based vaccines that occurred between February 2021 and April 2022. Musculoskeletal, pulmonary, cutaneous and cardiac manifestations, laboratory and imaging data were collected. RESULTS: In total, 15 cases of new onset myositis (11 polymyositis/necrotizing/overlap myositis; 4 dermatomyositis) were identified in the Yorkshire region of approximately 5.6 million people, between February 2021 and April 2022 (10 females/5 men; mean age was 66.1 years; range 37-83). New onset disease occurred after first vaccination (5 cases), second vaccination (7 cases) or after the third dose (3 cases), which was often a different vaccine. Of the cases, 6 had systemic complications including skin (3 cases), lung (3 cases), heart (2 cases) and 10/15 had myositis associated autoantibodies. All but 1 case had good therapy responses. Adverse event following immunization (AEFI) could not be explained based on the underlying disease/co-morbidities. CONCLUSION: Compared with our usual regional Rheumatology clinical experience, a surprisingly large number of new onset myositis cases presented during the period of observation. Given that antigen release inevitably follows muscle injury and given the role of nucleic acid adjuvanticity in autoimmunity and muscle disease, further longitudinal studies are required to explore potential links between novel coronavirus vaccines and myositis in comparison with more traditional vaccine methods.